BioSpace News Archive

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) to increase the maximum allowable dose of 60 mg with Palynziq® (pegvaliase-pqpz) Injection for treatment of adults with Phenylketonuria (PKU).

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a registered direct offering of $5.1 million of its common stock and warrants to purchase shares of common stock in a concurrent private placement.

Stephen A. Rosenberg, MD, PhD has been named the Philadelphia Academy of Surgery’s 2020 Samuel D. Gross Prize winner. The prize is accompanied by a $5,000 monetary award and will be presented on November 2, 2020.

Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a Total Potential of $17 Million

Swift Biosciences, Inc., a leader in the commercialization of DNA and RNA Library Preparation Kits introduces the new Swift 2S Sonic DNA Library Kit to the NGS Industry. After a tremendously successful debut of Swift 2S Turbo ‘s low-cost enzymatic fra

Q-Centrix®, the leading enterprise clinical quality data management provider in health care, announced it received the System and Organizational Controls (SOC) 2 compliance + HITRUST Common Security Framework (CSF) certification™

A study conducted by Millennium Health and published in Drug and Alcohol Dependence highlights the role real-time urine drug test results can play in identifying dangerous drug abuse trends including fentanyl analog positivity nationwide.

Qosina Corp. and its beauty division, Qosmedix, are proud to announce they have been awarded a bronze medal for Corporate Social Responsibility from EcoVadis, the world’s most trusted provider of business sustainability ratings. Qosina and Qosmedix were rated based on a sustainability scorecard which illustrates performance across 21 indicators in four main categories: environment, labor and human rights, ethics, an

Inositec, a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced that Michael H. Davidson, MD, has been appointed to the Board of Directors.

Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1